Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 334-338

  Leavey, Patrick J ^a   Mascarenhas, Leo ^b,c   Marina, Neyssa ^d   Chen, Zhengjia ^e   Krailo, Mark ^b,e   Miser, James ^f   Brown, Ken ^g   Tarbell, Nancy ^h   Bernstein, Mark L ⁱ   Granowetter, Linda ^j   Gebhardt, Mark ^k   Grier, Holcombe E ^k  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g BC CHILDREN S HOSPITAL   (Canada)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j Columbia Presbyterian College of Physicians and Surgeons ^*  (United States)

^k BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Children; Ewing sarcoma; Multi modality therapy; Prognostic factors for patients

Indexed keywords

ADULT; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; DISEASE FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PROGNOSIS; RECURRENCE; SARCOMA, EWING'S; SURVIVAL RATE;

EID: 48249151771     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21618     Document Type: Article

References (12)

1. Guerney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Gloecker Ries LA, Smith MA, Gurney JG, et al. editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. Bethesda: NCI; 1999. pp 99-110.
2. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
3. Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr Blood Cancer 2007; 49:894-900.
4. Bacci G, Mercuri M, Longhi A, et al. Neoadjuvant chemotherapy for Ewing's tumour of bone: Recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer 2002;38:2243-2251.
5. Shankar AG, Ashley S, Craft AW, et al. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003;40:141-147.
6. McTiernan AM, Cassoni AM, Driver D, et al. Improving outcomes after relapse in Ewing's Sarcoma: Analysis of 114 patients from a single institution. Sarcoma 2006;2006:1-8.
7. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:1654-1659.
8. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007;109:46-51.
9. Kalbfleisch JD, Prenttice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980.
10. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002;94:561-569.
11. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005;23:4354-4362.
12. Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: Analysis from INT-0091 - A report from the Children's Oncology Group. J Clin Oncol 2006;24:3838-3843.